Current status for the treatment of extranodal nasal type NK/T cell lymphoma

doi:10.3760/cma.j.issn.1673-422X.2015.07.022

Abstract

Abstract: The most of extranodal nasal type NK/Tcell lymphoma (ENKTL) are in the Ⅰ/Ⅱ stage. Radiotherapy alone is insufficient to achieve a high cure rate for the early stage patients with ENKTL due to frequent local and systemic relapse. Concomitant/sequential chemotherapy and radiotherapy is the standard treatment for the early stage patients with ENKTL. For the patients with stage Ⅲ/Ⅳ ENKTL, regimens containing Lasparaginase are most effective. For the patients with advanced stage ENKTL or refractory recurrent ENKTL, hematopoietic stem cell transplantation may be considered when the remission is achieved.

Key words: Lymphoma, extranodal NKTcell, Radiotherapy, Drug therapy, Hematopoietic stem cell transplantation

Tao Hengmin, Wei Yumei, Li Baosheng. Current status for the treatment of extranodal nasal type NK/T cell lymphoma[J]. Journal of International Oncology, 2015, 42(7): 554-556.

References

［1］ Au WY, Weisenburger DD, Intragumtornchai T, et al. Clinical differences between nasal and extranasal natural killer/Tcell lymphoma: a study of 136 cases from the international peripheral Tcell lymphoma project［J］. Blood, 2009, 113(17): 3931-3937. ［2］ Li YX, Yao B, Jin J, et al. Radiotherapy as primary treatment for stage ⅠE and ⅡE nasal natural killer/Tcell lymphoma［J］. J Clin Oncol, 2006, 24(1): 181-189. ［3］ Jiang L, Li SJ, Jiang YM, et al. The significance of combining radiotherapy with chemotherapy for early stage extranodal natural killer/Tcell lymphoma, nasal type: a systematic review and metaanalysis［J］. Leuk Lymphoma, 2014, 55(5): 1038-1048. ［4］ Li YX, Wang H, Jin J, et al. Radiotherapy alone with curative intent in patients with stage Ⅰ extranodal nasaltype NK/Tcell lymphoma［J］. Int J Radiat Oncol Biol Phys, 2012, 82(5): 1809-1815. ［5］聂大红, 谢方云, 李济时, 等. 早期鼻腔NK/T细胞淋巴瘤治疗方法和预后分析［J］. 中华放射肿瘤学杂志, 2010, 19(4): 315-319. ［6］ Lee J, Cho SG, Chung SM, et al. Retrospective analysis of treatment outcomes for extranodal NK/Tcell lymphoma (ENKL), nasal type, stage ⅠⅡE: single institute experience of combined modality treatment for early localized nasal extranodal NK/Tcell lymphoma (ENKL)［J］. Ann Hematol, 2013, 92(3): 333-343. ［7］ Yamaguchi M, Tobinai K, Oguchi M, et al. Phase Ⅰ/Ⅱ study of concurrent chemoradiotherapy for localized nasal natural killer/Tcell lymphoma: Japan clinical oncology group study JCOG0211［J］. J Clin Oncol, 2009, 27(33): 5594-5600. ［8］ Kim SJ, Kim K, Kim BS, et al. Phase Ⅱ trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage ⅠE to ⅡE, nasal, extranodal NK/Tcell lymphoma: consortium for improving survival of lymphoma study［J］. J Clin Oncol, 2009, 27(35): 6027-6032. ［9］ Kim SJ, Yang DH, Kim JS, et al. Concurrent chemoradiotherapy followed by Lasparaginasecontaining chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL0801 phase Ⅱ study［J］. Ann Hematol, 2014, 93(11): 1895-1901. ［10］王志辉, 夏忠军, 李苏, 等. 吉西他滨联合奥沙利铂及左旋门冬酰胺酶对Ⅰ/Ⅱ期结外NK/T细胞淋巴瘤的近期疗效及安全性分析［J］. 广东医学, 2011, 32(2): 240-242. ［11］ Jaccard A, Gachard N, Marin B, et al. Efficacy of Lasparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/Tcell lymphoma, a phase 2 study［J］. 2011, 117(6): 1834-1839. ［12］ Yong W , Zheng W, Zhu J, et al. Lasparaginase in the treatment of refractory and relapsed extranodal NK/Tcell lymphoma, nasal type［J］. Ann Hematol, 2009, 88(7): 647-652. ［13］周颖, 蔡清清, 林旭滨, 等. SMILE方案治疗复发难治NK/T细胞淋巴瘤的初步临床报告［J］. 白血病·淋巴瘤, 2009, 18, (4): 213-215. ［14］ Kwong YL, Kim WS, Lim ST, et al. SMILE for natural killer/Tcell lymphoma: analysis of safety and efficacy from the Asia lymphoma study group［J］. Blood, 2012, 120(15): 2973-2980. ［15］ Ennishi D, Maeda Y, Fujii N, et al. Allogeneic hematopoietic stem cell transplantation for advanced extranodal natural killer/Tcell lymphoma, nasal type［J］. Leuk Lymphoma, 2011, 52(7): 1255-1261. ［16］ Li M, Gao C, Li H, et al. Allogeneic haematopoietic stem cell transplantation as a salvage strategy for relapsed or refractory nasal NK/Tcell lymphoma［J］. Med Oncol, 2011, 28(3): 840-845. ［17］ Kwong YL, Anderson BO, Advani R, et al. Management of Tcell and naturalkillercell neoplasms in Asia: consensus statement from the Asian oncology summit 2009［J］. Lancet Oncol, 2009, 10(11): 1093-1101. ［18］ Suzuki R. Treatment of advanced extranodal NK/T cell lymphoma, nasaltype and aggressive NKcell leukemia［J］. Int J Hematol, 2010, 92(5): 697-701.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[4]	Qian Xiaotao, Shi Ziyi, Hu Ge. A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(3): 151-156.
[5]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing. Progress of radiotherapy in oligometastatic non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 170-174.
[6]	Yue Hongyun, Zhang Baihong. Differentiation therapies in human cancers [J]. Journal of International Oncology, 2024, 51(2): 109-113.
[7]	Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104.
[8]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei. Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients [J]. Journal of International Oncology, 2024, 51(1): 37-42.
[9]	Cui Tenglu, Lyu lu, Sun Pengfei. Application of radiotherapy combined with immunotherapy in the treatment of head and neck squamous cell carcinoma [J]. Journal of International Oncology, 2023, 50(9): 548-552.
[10]	Li Chenxi, Zhao Hongwei. Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery [J]. Journal of International Oncology, 2023, 50(6): 342-347.
[11]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[12]	Lyu Lu, Sun Pengfei. Gut flora and cervical cancer [J]. Journal of International Oncology, 2023, 50(6): 373-376.
[13]	Radiation Oncology Treatment Physician Branch, Chinese Medical Doctor Association, Radiation Oncology Therapy Branch, Chinese Medical Association, Chinese Association of Radiation Therapy, China Anti-Cancer Association. Chinese experts' consensus on the application of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy （2023 version） [J]. Journal of International Oncology, 2023, 50(4): 193-201.
[14]	Xu Meng, Jiang Wei, Zhu Haitao, Cao Xiongfeng. Research progress of cancer-associated fibroblasts in tumor radiotherapy resistance [J]. Journal of International Oncology, 2023, 50(4): 227-230.
[15]	Shi Xaioqi, Wang Hongyan. Research progress on the interaction between gut microbiota and radiation enteritis [J]. Journal of International Oncology, 2023, 50(4): 244-247.